Gromo G, Mann J, Fitzgerald J D
F. Hoffmann-La Roche AG, CH-4070 Basel, Switzerland.
Translational Medicine, Cardiovascular and Metabolism, F. Hoffmann-La Roche AG, CH-4070 Basel, Switzerland.
Cold Spring Harb Perspect Med. 2014 Jun 2;4(6):a014092. doi: 10.1101/cshperspect.a014092.
The theme of this review is to summarize the evolving processes in cardiovascular drug discovery and development within a large pharmaceutical company. Emphasis is placed on the contrast between the academic and industrial research operating environments, which can influence the effectiveness of research collaboration between the two constituencies, but which plays such an important role in drug innovation. The strategic challenges that research directors face are also emphasized. The need for improved therapy in many cardiovascular indications remains high, but the feasibility in making progress, despite the advances in molecular biology and genomics, is also assessed.
本综述的主题是总结一家大型制药公司心血管药物研发的演变过程。重点在于学术研究与产业研究运营环境之间的对比，这两者会影响两个群体间研究合作的成效，但在药物创新中却起着至关重要的作用。同时也强调了研究主管所面临的战略挑战。尽管分子生物学和基因组学取得了进展，但许多心血管适应症对改进治疗的需求仍然很高，本文也评估了取得进展的可行性。
